ArticleBlood cancer journal2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma.
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis.Journal of hematology & oncology · 2026Pooled it
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Pooled it
- Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.Blood advances · 2026Article
- Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.Alimentary pharmacology & therapeutics · 2026Review
- Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy.Nature medicine · 2026Article
- CART-immune-related adverse events after BCMA CAR-T therapy.Molecular therapy. Oncology · 2026Article
- Does ciltacabtagene autoleucel have a future in multiple myeloma?Nature reviews. Clinical oncology · 2026Article
- Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research · 2026Article
- Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias.Current hematologic malignancy reports · 2026Review
- Targeting BCMA in patients with relapsed/refractory multiple myeloma in 1 to 3 prior lines of therapy.Blood advances · 2026Review
- Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.Blood advances · 2026Article
- Navigating clinical decision-making for IEC-enterocolitis.Blood advances · 2026Article
- Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review.British journal of clinical pharmacology · 2026Review
- Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders.Nature reviews. Clinical oncology · 2026Review
- Review
- Article
- Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.Leukemia · 2026Review
- Cellular therapies for rheumatic disease.Current opinion in rheumatology · 2026Review
- Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series.Blood cancer journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22-210 days) after CAR-T therapy and a median of 85 days after cytokine release syndrome resolution. Gut biopsies uniformly demonstrated inflammation, including intra-epithelial lymphocytosis and villous blunting. In one case where CAR-specific immunofluorescence stains were available, CAR T-cell presence was confirmed within the lamina propria. Systemic corticosteroids were initiated in 10 patients (71%) a median of 25.5 days following symptom onset, with symptom improvement in 40%. Subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. Five patients (36%) have died from bowel perforation or treatment-emergent sepsis. In conclusion, IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy typically beginning 1-3 months after infusion. Thorough diagnostic workup is essential, including evaluation for potential T-cell malignancies. The early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.